Eli Lilly (LLY) Stock Climbs 5% on Strong Q1 Results and Upgraded Forecast

Table of Contents Eli Lilly delivered quarterly results that exceeded Wall Street expectations across the board. The pharmaceutical powerhouse outperformed on both revenue and earnings while simultaneously upgrading its annual outlook — a trifecta that pleased investors. $LLY (Eli Lilly) #earnings are out: pic.twitter.com/K7GBTJ8nOi — The Earnings Correspondent (@earnings_guy) April 30, 2026 The Indianapolis-based company announced adjusted earnings of $8.55 per share for the first quarter of 2026, comfortably surpassing the Street’s $6.97 expectation by $1.58. Top-line performance reached $19.8 billion, crushing the $17.6 billion forecast and marking a substantial 56% climb from the $12.7 billion reported in the year-ago quarter. The impressive revenue expansion stemmed primarily from volume increases — which jumped 65% — although pricing concessions on key products Mounjaro and Zepbound created a 13 percentage point headwind. Mounjaro, the company’s diabetes treatment, generated $8.7 billion in sales, reflecting a remarkable 125% increase. Meanwhile, Zepbound, positioned for weight management, delivered $4.2 billion in revenue with an 80% uptick. Eli Lilly and Company, LLY Domestic sales expanded 43% to reach $12.1 billion. Markets outside the United States contributed $7.7 billion, up 81%, demonstrating the global appetite for GLP-1 therapies. Adjusted gross margin registered at 82.6%, declining modestly from the previous year as pricing dynamics on leading products created margin pressure. Chief Executive David Ricks highlighted the momentum. “We delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion,” he stated. Lilly increased its 2026 revenue forecast to $82.0–$85.0 billion from the earlier $80.0–$83.0 billion range. The midpoint of $83.5 billion exceeds Wall Street’s consensus estimate of $81.67 billion. The company also elevated its adjusted EPS guidance to $35.50–$37.00, up from $33.50–$35.00 previously, with the revised midpoint of $36.25 beating the consensus of $34.53. The company’s recently introduced oral GLP-1 medication Foundayo launched in early April, attracting significant attention as a competitive response to Novo Nordisk, which has established an early presence in the oral weight-loss medication category. Foundayo captured 3,707 prescriptions across the United States during the week that concluded April 17 — approximately half the ~8,000 prescriptions Wall Street anticipated. This underwhelming initial performance represents a potential concern for market observers. Ricks characterized the medication as one that will “meaningfully expand the number of people who can benefit from GLP-1s,” emphasizing its convenience: patients can take it at any point during the day, without dietary or hydration restrictions — differentiating it from competing oral GLP-1 treatments. Shares climbed more than 5% during premarket trading following the earnings announcement, though gains moderated somewhat as regular trading commenced.